Stockscreener 앱 받기
9.04
2.38%
0.21
시장 영업 전:
8.80
-0.24
-2.65%
전일 마감가:
$8.83
열려 있는:
$8.79
하루 거래량:
1.49M
Relative Volume:
1.20
시가총액:
$790.98M
수익:
-
순이익/손실:
$-185.15M
주가수익비율:
-4.4635
EPS:
-2.0253
순현금흐름:
$-148.72M
1주 성능:
-8.69%
1개월 성능:
-13.33%
6개월 성능:
-35.10%
1년 성능:
+8.26%
1일 변동 폭
$8.59
$9.27
1주일 범위
$8.59
$10.13
52주 변동 폭
$6.65
$36.26
올레마 Stock (OLMA) Company Profile
명칭
Olema Pharmaceuticals Inc
전화
(415) 651-3316
주소
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
9.04 | 790.98M | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
올레마 Stock (OLMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Wolfe Research | Peer Perform |
| 2026-03-19 | 재개 | Jefferies | Buy |
| 2026-02-11 | 개시 | Stifel | Buy |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-10-08 | 개시 | Guggenheim | Buy |
| 2025-08-12 | 재확인 | Citigroup | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2024-01-30 | 개시 | Citigroup | Buy |
| 2023-07-21 | 개시 | Oppenheimer | Outperform |
| 2023-05-05 | 개시 | CapitalOne | Overweight |
| 2023-02-22 | 개시 | Credit Suisse | Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 개시 | H.C. Wainwright | Neutral |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2020-12-14 | 개시 | Canaccord Genuity | Buy |
| 2020-12-14 | 개시 | Cowen | Outperform |
| 2020-12-14 | 개시 | JP Morgan | Overweight |
| 2020-12-14 | 개시 | Jefferies | Buy |
모두보기
올레마 주식(OLMA)의 최신 뉴스
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 7.1%Time to Sell? - MarketBeat
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Olema Pharmaceuticals at H.C. Wainwright: pipeline bets on breast cancer By Investing.com - Investing.com Canada
Olema Pharmaceuticals (OLMA) Slips to $9.75 as Shares Sit Mid-Range Between Key LevelsBreak of Structure - dars.gov.et
Goldman Sachs Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA) - The Globe and Mail
OLMA Maintained by Stifel -- Price Target Lowered to $30 - GuruFocus
Stifel cuts Olema Pharmaceuticals price target on trial concerns By Investing.com - Investing.com Nigeria
Why is Olema Pharmaceuticals stock sliding today? By Investing.com - Investing.com Canada
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results - finance.yahoo.com
Olema Pharmaceuticals (OLMA) Shares Drop 15% After AstraZeneca B - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 4.4%Here's Why - MarketBeat
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $59 - Moomoo
Olema Pharmaceuticals, Inc. $OLMA Shares Sold by Squarepoint Ops LLC - MarketBeat
OLMA: Phase III breast cancer trials for palazestrant target over $15B in global market opportunities - TradingView
Olema Oncology at citigroup summit: palazestrant data, delays - Investing.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 3.5%Should You Buy? - MarketBeat
Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1'27 (NASDAQ:OLMA) - Seeking Alpha
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne - quiverquant.com
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036 - Stock Titan
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Olema Pharmaceuticals Inc. (OLMA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BlackRock Inc. Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals Inc. (OLMA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Jupiter Topco LLC Takes $88.80 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of America Corp DE Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. OLMA Stock Forecast & Price Target - Yahoo! Finance Canada
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Olema Oncology appoints Jason O’Byrne as CFO - The Pharma Letter
OLMA Maintained by JP Morgan -- Price Target Lowered to $46.00 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals, Inc. Announces Appointment of Jason O?Byrne to Chief Financial Officer, Effective August 11, 2026 - marketscreener.com
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46 - moomoo.com
Olema Pharmaceuticals Names Jason O'Byrne as New CFO with Comprehensive Compensation Package - Kalkine Media
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
HC Wainwright Brokers Decrease Earnings Estimates for OLMA - MarketBeat
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - The Manila Times
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech - Stock Titan
Olema Pharmaceuticals Names Jason O'Byrne CFO - finance.yahoo.com
Olema Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harmon Cyrus - Moomoo
Olema stock falls 12.9% as Q2 loss widens to $63.2M on R&D spend - scanx.trade
OLMA Maintains Rating by Citigroup -- Price Target Lowered to $5 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup - MarketBeat
올레마 (OLMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.87%
자본화:
|
볼륨(24시간):